328
Participants
Start Date
April 5, 2019
Primary Completion Date
May 1, 2023
Study Completion Date
May 1, 2023
teplizumab
Treatment
Placebo
Control
UZ Brussel - Campus Jette (Site 202), Brussels
CHU UCL Namur, site Clinique Sainte-Elisabeth (Site 205), Namur
Hopitaux Pediatriques de Nice CHU-Lenval service de diabetologie et d'endocrinologia (Site 508), Nice
UZ Gent (Site 206), Ghent
CHU Hopital de la Timone-Hopital d'Enfants (Site 512), Marseille
Women and Children's Hospital of Buffalo (Site 010), Buffalo
Childrens Hospital of Philadelphia - Endocrinology (Site 021), Philadelphia
Capital Diabetes & Endocrine Associates (Site 029), Camp Springs
CHU DIJON hopital d'enfant (Site 504), Dijon
UNC Hospitals Children's Specialty Clinic (Site 038), Chapel Hill
Kinderkrankenhaus Auf Der Bult (Site 604), Hanover
Atlanta Diabetes Associates (Site 009), Atlanta
Centricity Research (Site 006), Columbus
Nemours Children's Specialty Care-Endocrinology (Site 047), Jacksonville
UF Clinical and Translation Research Building (Site 015), Gainesville
University of Miami Health System (Site 028), Miami
University of South Florida Diabetes and Endocrinology Center (Site 011), Tampa
Evangelisches Klinikum Bethel Kinderklinik (Site 602), Bielefeld
All Children's Hospital-Johns Hopkins Medicine (Site 048), St. Petersburg
Vanderbilt University Medical Center (Site 024), Nashville
AM Diabetes & Endocrinology Center (Site 008), Bartlett
Rainbow Babies & Children's Hospital (Site 049), Cleveland
Cleveland Clinic (Site 051), Cleveland
Centre Hospitalier Regional (CHR) d'Orleans-Service de pediatrie (Site 513), Orléans
Indiana University Hospital and Riley Hospital for Children (Site 014), Indianapolis
U. Iowa Children's Hospital (Site 023), Iowa City
U. Minnesota Health Clinical Research Unit (Site 031), Minneapolis
Sanford Diabetes and Thyroiid Clinical (Site 013), Sioux Falls
University of Chicago Medical Center (Site 017), Chicago
Washington University School of Medicine (Site 018), St Louis
Centre hospitalier de Pau (Site 501), Pau
Children's Mercy Hospitals & Clinics (Site 026), Kansas City
Universitätsklinikum Heidelberg (Site 608), Heidelberg
Groupe hospitalier Est-Hopital Femme, Mere, Enfant (Site 509), Bron
Groupe Hospitalier Necker Enfants Malades (site 502), Paris
Children's Medical Center Dallas (Site 033), Dallas
Universitätsklinikum Freiburg (Site 603), Freiburg im Breisgau
University of Colorado-Barbara Davis Center for Childhood Diabetes (Site 005), Aurora
St. Luke's Children's Endocrinology (Site 052), Boise
Rocky Mountain Diabetes and Osteoporosis Center (Site 007), Idaho Falls
Universitätsklinikum Augsburg (Site 606), Augsburg
Rady Children's Hospital-San Diego (Site 004), San Diego
UCSF Medical Center (Site 001), San Francisco
Diablo Clinical Research, Inc. (Site 002), Walnut Creek
Endocrinology Service Northwest, LLC (Site 034), Bend
Benaroya Research Institute at Virginia Mason (Site 016), Seattle
MultiCare Institute for Research & Innovation (Site 003), Tacoma
Yale University of Medicine (Site 020), New Haven
Baystate Pediatric Endocrinology & Diabetes (Site 040), Springfield
Alberta Diabetes Institute Clinical Research Unit Li Ka Shing Centre for Health Research Innovation (Site 103), Edmonton
BC Diabetes (Site 102), Vancouver
Montreal Children's Hospital-McGill (Site 101), Montreal
Békés Megyei Központi Kórház Pándy Kálmán Tagkórház ( Site 705), Gyula
Fakultni nemocnice v Motole (Site 301), Prague
Universitatsklinikum Carl Gustav Carus (Site 601), Dresden
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu (Site 804), Warsaw
Instytut Diabetologii Sp. z o.o. (Site 802), Warsaw
"Instytut Pomnik - Centrum Zdrowia Dziecka (Site 801)", Warsaw
Uniwersyteckie Centrum Kliniczne (Site 803), Warsaw
Northwick Park Hospital - Paediatrics (site 904), London
Cardiff and Vale NHS Trust - University Hospital of Wales (Site 902), Cardiff
Sheffield Children's NHS Foundation Trust Western Bank (Site 903), Sheffield
Provention Bio, Inc.
INDUSTRY